MUSC& Oxford Laboratories | United States
Dr. Mark T. Hamann is a distinguished scientist in drug discovery and biomedical sciences, holding the Charles and Carol Cooper/SmartState Endowed Chair at the Medical University of South Carolina (MUSC). With over 330 peer-reviewed publications and an h-index of 71, he ranks in the top 1% of scientists worldwide. His research focuses on marine natural products, drug discovery, and biomedical informatics, contributing significantly to cancer therapeutics, infectious diseases, and neurodegenerative disorders.
Profile
Google Scholar
ORCID
Scopus
Strengths for the Awards
- Outstanding Research Metrics
- h-index: 71 (Indicates a high impact and influence in the research community).
- i10-index: 200 (Signifies a significant number of highly cited papers).
- Citations: Over 18,100 (Reflects global recognition and influence).
- ResearchGate Score: Higher than 99% of RG readers.
- Stanford-PLOS One Report Ranking: Top 1% of scientists worldwide.
- Extensive Publication Record
- 330+ peer-reviewed publications and book chapters.
- Published in prestigious journals like Chemical Reviews, Journal of Natural Products, Molecular Oncology, and Scientific Reports.
- Frequent first and corresponding authorship roles.
- Leadership in Research and Academia
- Endowed Chair Professor at the Medical University of South Carolina.
- Holds multiple academic appointments across institutions.
- Leads research programs in drug discovery, pharmacognosy, marine natural products, and biomedical sciences.
- Founder and Chief Scientific Officer of Sycamore Biopharma and Oxford Laboratories.
Education 🎓
- Postdoctoral Research (1993) – Marine Natural Products, McMurdo, Antarctica & University of Hawaii, Honolulu
- Ph.D. in Organic Chemistry (1992) – University of Hawaii, under the guidance of Professor Emeritus Paul Scheuer
- B.S. in Chemistry and Biology (1985) – Bemidji State University, Minnesota
Experience 🏛️
Dr. Hamann has held various prestigious academic and research positions, including:
- Professor of Drug Discovery & Biomedical Sciences, MUSC
- Director of Clinical Studies, Branded Legacy, Inc. (2024–Present)
- Cofounder & CSO, Sycamore Biopharma & Oxford Laboratories (acquired by Branded Legacy in 2024)
- Joint Appointed Professor, Clemson-MUSC Biomedical Data Sciences & Informatics Program
- Adjunct Professor, College of Charleston & University of Maryland Center for Environmental Science
- Principal Investigator, Bigelow Marine Laboratory
His work spans pharmacology, marine biotechnology, and biomedical sciences, focusing on translational research from lab discoveries to clinical applications.
Research Interests On Toxicology 🔬
Dr. Hamann’s research revolves around:
- Marine Natural Products – Identifying bioactive compounds from marine organisms for therapeutic use.
- Cancer Therapeutics – Developing novel anticancer agents, particularly targeting drug-resistant tumors.
- Infectious Diseases & COVID-19 Research – Investigating antiviral compounds, including inhibitors for SARS-CoV-2.
- Biomedical Informatics & AI in Drug Discovery – Harnessing computational tools for accelerating pharmaceutical innovation.
Awards & Honors 🏆
Dr. Hamann has received numerous accolades, including:
- Presidential Candidate Nomination, American Society of Pharmacognosy (2024/2025)
- MUSC College of Pharmacy Researcher of the Year (2024)
- Stanford-PLOS One Report – Ranked in the top 1% of scientists globally
- Lifetime Membership Award, International Marine Biotechnology Association (2020)
- Best Publication of the Year (2021) – Journal of Antibiotics, Nature Publishing
- Chair & Member of NIH, NCCIH, and NIDA Study Sections (2020-2024)
Publications 📚
- Marine indole alkaloids: potential new drug leads for the control of depression and anxiety
- Authors: AJ Kochanowska-Karamyan, MT Hamann
- Year: 2010
- Citations: 2001
- Lamellarins and related pyrrole-derived alkaloids from marine organisms
- Authors: H Fan, J Peng, MT Hamann, JF Hu
- Year: 2008
- Citations: 1159
- Marine natural products and their potential applications as anti-infective agents
- Authors: M Donia, MT Hamann
- Year: 2003
- Citations: 736
- Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases
- Authors: W Gul, MT Hamann
- Year: 2005
- Citations: 538
- Marine natural products as novel antioxidant prototypes
- Authors: S Takamatsu, TW Hodges, I Rajbhandari, WH Gerwick, MT Hamann, …
- Year: 2003
- Citations: 364
- Marine pharmacology in 2005–6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis …
- Authors: AMS Mayer, AD Rodríguez, RGS Berlinck, MT Hamann
- Year: 2009
- Citations: 354
- Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp
- Authors: MT Hamann, PJ Scheuer
- Year: 1993
- Citations: 353
- Marine pharmacology in 2001–2002: Marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet …
- Authors: AMS Mayer, MT Hamann
- Year: 2005
- Citations: 345
- Kahalalides: Bioactive Peptides from a Marine Mollusk Elysia rufescens and Its Algal Diet Bryopsis sp.
- Authors: MT Hamann, CS Otto, PJ Scheuer, DC Dunbar
- Year: 1996
- Citations: 336
- In vivo antimalarial activity of the beta-carboline alkaloid manzamine A
- Authors: KKH Ang, MJ Holmes, T Higa, MT Hamann, UAK Kara
- Year: 2000
- Citations: 315
Conclusion 🌍
Dr. Mark T. Hamann is a pioneering scientist whose work has had a lasting impact on drug discovery, cancer therapeutics, and marine natural products research. His dedication to translational science and mentorship continues to shape the future of pharmaceutical innovations.
